3653 results for «445»

Filter By

3653 results

EuroPCR 2017 Nurses and Allied Professionals Programme Closing Ceremony

19 May 2017 – From EuroPCR 2017

Consult the session on the Closing Ceremony of the EuroPCR 2017 Nurses and Allied Professionals Programme, presented by S. Coelho, H. Eltchaninoff and D. Sparv. The State-of-the-art lecture on structural heart disease by Prof. A. Cribier sheds light on LAA occlusion.

EuroPCR 2017 Closing Ceremony

19 May 2017 – From EuroPCR 2017

EuroPCR 2017 Closing

Opening ceremony

08 Apr 2017 – From PCR Tokyo Valves 2017

Closing Ceremony and Awards

09 Apr 2017 – From PCR Tokyo Valves 2017

Elixir Medical To Announce Late-Breaking Clinical Data at EuroPCR 2023 Session Featuring World’s First Transforming Coronary Artery Implant Designed to Restore Vessel Physiology and Function

09 May 2023

EuroPCR 2025: Late-breaking data demonstrate sustained significantly lower event rates with Elixir Medical’s DynamX® Bioadaptor over drug-eluting stent through three Years

21 May 2025

EuroPCR 2026: Elixir Medical's DynamX® bioadaptor demonstrates significantly lower event rates than drug-eluting stent in long-term follow-up, including reduction in cardiovascular death

19 May 2026

Promising Safety and Efficacy Results for Supraflex Cruz in HBR Subset Analysis from FIRE Trial, with 1-Month DAPT

03 Nov 2023

A randomised, multicenter, non-inferiority comparison of intravascular lithotripsy and super-high-pressure non-compliant balloons for treatment of calcified and refractory coronary lesions - The VICTORY trial

27 Oct 2025

Mirvat Alasnag provides her take on the VICTORY trial presented by Matthias Bossard at TCT 2025 in San Francisco.

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
VICTORY: Intravascular lithotripsy vs. super-high-pressure PTCA in calcified and refractory coronary lesions

Positive 3-year results from FIRE Trial demonstrate Supraflex Cruz’s safety and efficacy in elderly heart attack patients

26 Sep 2025

EuroPCR 2024: Late-breaking data demonstrate significant clinical advantage of Elixir Medical’s DynamX bioadaptor over standard-of-care drug-eluting stent at two years

14 May 2024

Elixir Medical’s DynamX Bioadaptor demonstrates significant improvement over contemporary drug-eluting stent in patients with acute coronary syndrome and complex lesion subsets after six months

28 Oct 2024

EuroPCR 2023: Late-Breaking Clinical Data Demonstrate Elixir Medical’s DynamX Bioadaptor Restores Vessel Motion and Function with Better Effectiveness at 12 Months Compared to a Leading Drug-Eluting Stent (DES)

17 May 2023

Didn’t find what you were looking for?